Comparative analysis of adeno-associated virus capsid stability and dynamics

Journal of Virology

Volumn 87, Issue 24, 2013, Pages 13150-13160

  Rayaprolu, Vamseedhar ^a   Kruse, Shannon ^a   Kant, Ravi ^a   Venkatakrishnan, Balasubramanian ^b   Movahed, Navid ^a   Brooke, Dewey ^a   Lins, Bridget ^b   Bennett, Antonette ^b   Potter, Timothy ^a   McKenna, Robert ^b   Agbandje McKenna, Mavis ^b   Bothner, Brian ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; PHOSPHOLIPASE; VIRUS PROTEIN;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 1; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ADENO ASSOCIATED VIRUS 8; ARTICLE; COMPARATIVE STUDY; DIFFERENTIAL SCANNING CALORIMETRY; ELECTRON MICROSCOPY; FLUOROMETRY; GENE THERAPY; HOST CELL; MELTING POINT; NONHUMAN; OPEN READING FRAME; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; SEROTYPE; THERMODYNAMICS; THERMOSTABILITY; VIRUS CAPSID; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY;

CALORIMETRY, DIFFERENTIAL SCANNING; CAPSID; CAPSID PROTEINS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; MICROSCOPY, ELECTRON; PROTEIN STABILITY;

EID: 84888074616     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01415-13     Document Type: Article

References (106)

1. Halder S, Ng R, Agbandje-McKenna M. 2012. Parvoviruses:structure and infection. Future Virol. 7:253-278.
2. Muzyczka N, Berns KI. 2001. Parvoviridae:the viruses and their replication, p 2327-2360. In Knipe DM, HowleyPM(ed), Fields virology, 4th ed. Lippincott Williams and Wilkins, New York, NY.
3. Agbandje-McKenna M, Kleinschmidt J. 2011. AAV capsid structure and cell interactions. Methods Mol. Biol. 807:47-92.
4. Agbandje-McKenna M, Chapman MS. 2006. Correlating structure with function in the viral capsid, p 125-139. In Kerr JR, Cotmore SF, Bloom ME, Linden R, Parrish CR (ed), Parvoviruses. Hodder Arnold Publication, London, United Kingdom.
5. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. 2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78:6381-6388.
6. Gao G-P, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99:11854-11859.
7. Mori S, Wang L, Takeuchi T, Kanda T. 2004. Two novel adenoassociated viruses from cynomolgus monkey:pseudotyping characterization of capsid protein. Virology 330:375-383.
8. Reference deleted.
9. Schmidt M, Voutetakis A, Afione S, Zheng C, Mandikian D, Chiorini JA. 2008. Adeno-associated virus type 12 (AAV12):a novel AAV serotype with sialic acid-and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82:1399-1406.
10. Van Vliet KM, Blouin V, Brument N, Agbandje-McKenna M, Snyder RO. 2008. The role of the adeno-associated virus capsid in gene transfer. Methods Mol. Biol. 437:51-91.
11. Mingozzi F, High KA. 2011. Therapeutic in vivo gene transfer for genetic disease using AAV:progress and challenges. Nat. Rev. Genet. 12:341-355.
12. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma J, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. 2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358:2240-2248.
13. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. 2000. Several log increase in therapeutic transgene delivery by distinct adenoassociated viral serotype vectors. Mol. Ther. 2:619.
14. Davidson BL, Stein CS, Heth JA, Kotin RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA. 2000. Recombinant adeno-associated virus type 2, 4, and 5 vectors:transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U.S.A. 97:3428-3432.
15. Kern A, Schmidt K, Leder C, Muller OJ, Wobus CE, Bettinger K, Von der Lieth CW, King JA, Kleinschmidt JA. 2003. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77:11072-11081.
16. Levy HC, Bowman VD, Govindasamy L, McKenna R, Nash K, Warrington K, Chen W, Muzyczka N, Yan X, Baker TS, Agbandje-McKenna M. 2009. Heparin binding induces conformational changes in adeno-associated virus serotype 2. J. Struct. Biol. 165:146.
17. Opie SR, Warrington JKH, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. 2003. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77:6995-7006.
18. Summerford C, Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-1445.
19. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 80:9831-9836.
20. Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ. 2006. Adeno-associated virus type 2 contains an integrin α5β1 binding domain essential for viral cell entry. J. Virol. 80:8961-8969.
21. Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai Y, Shimada T, Matsumoto K, Nakamura T, Watanabe M, Oshimi K, Daida H. 2005. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J. Virol. 79:609-614.
22. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. 1999. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5:71-77.
23. Reference deleted.
24. Reference deleted.
25. Summerford C, Bartlett JS, Samulski RJ. 1999. αVβ5 integrin:a coreceptor for adeno-associated virus type 2 infection. Nat. Med. 5:78-82.
26. Nonnenmacher M, Weber T. 2011. Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe 10:563-576.
27. Lerch TF, Xie Q, Chapman MS. 2010. The structure of adenoassociated virus serotype 3B (AAV-3B):insights into receptor binding and immune evasion. Virology 403:26-36.
28. Blackburn SD, Steadman RA, Johnson FB. 2006. Attachment of adenoassociated virus type 3H to fibroblast growth factor receptor 1. Arch. Virol. 151:617.
29. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. 2001. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75:6884-6893.
30. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ. 2006. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80:9093-9103.
31. Walters RW, Yi SMP, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA, Zabner J. 2001. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J. Biol. Chem. 276:20610-20616.
32. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA. 2003. Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 9:1306-1312.
33. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. 2011. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286:13532-13540.
34. Sonntag F, Bleker S, Leuchs B, Fischer R, Kleinschmidt AJ. 2006. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J. Virol. 80:11040-11054.
35. Buller RM, Rose JA. 1978. Characterization of adenovirus-associated virus-induced polypeptides in KB cells. J. Virol. 25:331-338.
36. Rose JA, Maizel JV, Inman JK, Shatkin AJ. 1971. Structural proteins of adenovirus-associated viruses. J. Virol. 8:766-770.
37. Chapman MS, Agbandje-McKenna M. 2006. Atomic structure of viral particles, p 107-123. In Kerr JR, Cotmore SF, Bloom ME, Linden R, Parrish CR (ed), Parvoviruses. Edward Arnold Ltd., New York, NY.
38. Naumer M, Sonntag F, Schmidt K, Nieto K, Panke C, Davey NE, Popa-Wagner R, Kleinschmidt JA. 2012. Properties of the AAV assembly-activating protein AAP. J. Virol. 86:13038-13048.
39. Salganik M, Venkatakrishnan B, Bennett A, Lins B, Yarbrough J, Muzyczka N, Agbandje-McKenna M, McKenna R. 2012. Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J. Virol. 86:11877-11885.
40. Van Vliet K, Blouin V, Agbandje-McKenna M, Snyder RO. 2006. Proteolytic mapping of the adeno-associated virus capsid. Mol. Ther. 14:809.
41. Popa-Wagner R, Porwal M, Kann M, Reuss M, Weimer M, Florin L, Kleinschmidt JA. 2012. Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J. Virol. 86:9163-9174.
42. Bleker S, Pawlita M, Kleinschmidt JA, Kleinschmidt A. 2006. Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging. J. Virol. 80:810-820.
43. Govindasamy L, Padron E, McKenna R, Muzyczka N, Kaludov N, Chiorini JA, Agbandje-McKenna M. 2006. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 80:11556-11570.
44. Ng R, Govindasamy L, Gurda BL, McKenna R, Kozyreva OG, Samulski RJ, Parent KN, Baker TS, Agbandje-McKenna M. 2010. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J. Virol. 84:12945-12957.
45. Walters RW, Agbandje-McKenna M, Bowman VD, Moninger TO, Olson NH, Seiler M, Chiorini JA, Baker TS, Zabner J. 2004. Structure of adeno-associated virus serotype 5. J. Virol. 78:3361-3371.
46. Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS. 2002. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99:10405-10410.
47. Nam H-J, Lane MD, Padron E, Gurda B, McKenna R, Kohlbrenner E, Aslanidi G, Byrne B, Muzyczka N, Zolotukhin S, Agbandje-McKenna M. 2007. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 81:12260-12271.
48. Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ. 2006. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80:11393-11397.
49. Reference deleted.
50. Reference deleted.
51. DiMattia M, Govindasamy L, Levy HC, Gurda-Whitaker B, Kalina A, Kohlbrenner E, Chiorini JA, McKenna R, Muzyczka N, Zolotukhin S, Agbandje-McKenna M. 2005. Production, purification, crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 5. Acta Crystallogr. Sect. F 61:917-921.
52. Kohlbrenner E, Aslanidi G, Nash K, Shklyaev S, Campbell-Thompson M, Byrne BJ, Snyder RO, Muzyczka N, Warrington KH, Zolotukhin S. 2005. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol. Ther. 12:1217-1225.
53. Lane MD, Nam H-J, Padron E, Gurda-Whitaker B, Kohlbrenner E, Aslanidi G, Byrne B, McKenna R, Muzyczka N, Zolotukhin S, Agbandje-McKenna M. 2005. Production, purification, crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8. Acta Crystallogr. Sect. F 61:558-561.
54. Miller EB, Gurda-Whitaker B, Govindasamy L, McKenna R, Zolotukhin S, Muzyczka N, Agbandje-McKenna M. 2006. Production, purification and preliminary X-ray crystallographic studies of adenoassociated virus serotype 1. Acta Crystallogr. Sect. F 62:1271-1274.
55. Mah C, Fraites JTJ, Zolotukhin I, Song S, Flotte TR, Dobson J, Batich C, Byrne BJ. 2002. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol. Ther. 6:106-112.
56. Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ, Chiodo VA, Phillipsberg T, Muzyczka N, Hauswirth WW, Flotte TR, Byrne BJ, Snyder RO. 2002. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28:158-167.
57. Yeh AP, McMillan A, Stowell MHB. 2006. Rapid and simple proteinstability screens:application to membrane proteins. Acta Crystallogr. D Biol. Crystallogr. 62:451-457.
58. Reference deleted.
59. Nelson CDS, Minkkinen E, Bergkvist M, Hoelzer K, Fisher M, Bothner B, Parrish CR. 2008. Detecting small changes and additional peptides in the canine parvovirus capsid structure. J. Virol. 82:10397-10407.
60. Reference deleted.
61. Bothner B, Schneemann A, Marshall D, Reddy V, Johnson JE, Siuzdak G. 1999. Crystallographically identical virus capsids display different properties in solution. Nat. Struct. Mol. Biol. 6:114-116.
62. Rayaprolu V, Manning BM, Douglas T, Bothner B. 2010. Virus particles as active nanomaterials that can rapidly change their viscoelastic properties in response to dilute solutions. Soft Matter 6:5286-5288.
63. Belnap DM, Filman DJ, Trus BL, Cheng N, Booy FP, Conway JF, Curry S, Hiremath CN, Tsang SK, Steven AC, Hogle JM. 2000. Molecular tectonic model of virus structural transitions:the putative cell entry states of poliovirus. J. Virol. 74:1342-1354.
64. Gan L, Speir JA, Conway JF, Lander G, Cheng N, Firek BA, Hendrix RW, Duda RL, Liljas L, Johnson JE. 2006. Capsid conformational sampling in HK97 maturation visualized by X-ray crystallography and cryo-EM. Structure 14:1655-1665.
65. Horowitz ED, Rahman KS, Bower BD, Dismuke DJ, Falvo MCR, Griffith JD, Harvey SC, Asokan A. 2013. Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. J. Virol. 87:2994-3002.
66. Wu P, Xiao WW, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N. 2000. Mutational analysis of the adenoassociated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74:8635-8647.
67. Endres D, Zlotnick A. 2002. Model-based analysis of assembly kinetics for virus capsids or other spherical polymers. Biophys. J. 83:1217-1230.
68. Zlotnick A. 2003. Are weak protein-protein interactions the general rule in capsid assembly? Virology 315:269-274.
69. Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR. 2006. Conformational stability and disassembly of Norwalk virus-like particles. J. Biol. Chem. 281:19478-19488.
70. Carrillo-Tripp M, Shepherd CM, Borelli IA, Venkataraman S, Lander G, Natarajan P, Johnson JE, Brooks CL, Reddy VS. 2009. VIPERdb2:an enhanced and web API enabled relational database for structural virology. Nucleic Acids Res. 37:D436-D442.
71. Bothner B, Dong XF, Bibbs L, Johnson JE, Siuzdak G. 1998. Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry. J. Biol. Chem. 273:673-676.
72. Hilmer JK, Zlotnick A, Bothner B. 2008. Conformational equilibria and rates of localized motion within hepatitis B virus capsids. J. Mol. Biol. 375:581-594.
73. Park C, Marqusee S. 2004. Probing the high energy states in proteins by proteolysis. J. Mol. Biol. 343:1467-1476.
74. Venkatakrishnan B, Yarbrough J, Domsic J, Bennett A, Bothner B, Kozyreva OG, Samulski RJ, Muzyczka N, McKenna R, Agbandje-McKenna M. 2013. Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J. Virol. 87:4974-4984.
75. Kronenberg S, Bottcher B, von der Lieth CW, Bleker S, Kleinschmidt JA. 2005. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J. Virol. 79:5296-5303.
76. Akache B, Grimm D, Shen X, Fuess S, Yant SR, Glazer DS, Park J, Kay MA. 2007. A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol. Ther. 15:330-339.
77. Caspar DL, Klug A. 1962. Physical principles in the construction of regular viruses. Cold Spring Harbor Symp. Quant. Biol. 27:1-24.
78. Fricks CE, Hogle JM. 1990. Cell-induced conformational change in poliovirus:externalization of the amino terminus of VP1 is responsible for liposome binding. J. Virol. 64:1934-1945.
79. Fricks CE, Icenogle JP, Hogle JM. 1985. Trypsin sensitivity of the Sabin strain of type 1 poliovirus:cleavage sites in virions and related particles. J. Virol. 54:856-859.
80. Golden JS, Harrison SC. 1982. Proteolytic dissection of turnip crinkle virus subunit in solution. Biochemistry 21:3862-3866.
81. Johnson JE. 2003. Virus particle dynamics. Adv. Protein Chem. 64:197-218.
82. Kowalski H, Maurer-Fogy I, Vriend G, Casari G, Beyer A, Blaas D. 1989. Trypsin sensitivity of several human rhinovirus serotypes in their low pH-induced conformation. Virology 171:611-614.
83. Horton N, Lewis M. 1992. Calculation of the free energy of association for protein complexes. Protein Sci. 1:169-181.
84. Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ, Wasney GA, Yeung R, Arrowsmith C, Ball LJ, Berglund H, Hui R, Marsden BD, Nordlund P, Sundstrom M, Weigelt J, Edwards AM. 2006. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. U.S.A. 103:15835-15840.
85. Yi G, Vaughan RC, Yarbrough I, Dharmaiah S, Kao CC. 2009. RNA binding by the brome mosaic virus capsid protein and the regulation of viral RNA accumulation. J. Mol. Biol. 391:314-326.
86. Nam H-J, Gurda BL, McKenna R, Potter M, Byrne B, Salganik M, Muzyczka N, Agbandje-McKenna M. 2011. Structural studies of adenoassociated virus serotype 8 capsid transitions associated with endosomal trafficking. J. Virol. 85:11791-11799.
87. Bleker S, Sonntag F, Kleinschmidt JA, Kleinschmidt A. 2005. Mutational analysis of narrow pores at the fivefold symmetry axes of adenoassociated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 Activity. J. Virol. 79:2528-2540.
88. Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, Surosky R, Pierce GF, Colosi P. 2006. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80:821-834.
89. Skehel JJ, Bayley PM, Brown EB, Martin SR, Waterfield MD, White JM, Wilson IA, Wiley DC. 1982. Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc. Natl. Acad. Sci. U.S.A. 79:968-972.
90. Gurda BL, Raupp C, Popa-Wagner R, Naumer M, Olson NH, Ng R, McKenna R, Baker TS, Kleinschmidt JA, Agbandje-McKenna M. 2012. Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J. Virol. 86:7739-7751.
91. Raupp C, Naumer M, Müller OJ, Gurda BL, Agbandje-McKenna M, Kleinschmidt JA. 2012. The threefold protrusions of AAV8 are involved in cell surface targeting as well as post attachment processing. J. Virol. 86:9396-9408.
92. Farr GA, Tattersall P. 2004. A conserved leucine that constricts the pore through the capsid fivefold cylinder plays a central role in parvoviral infection. Virology 323:243-256.
93. Bothner B, Taylor D, Jun B, Lee KK, Siuzdak G, Schlutz CP, Johnson JE. 2005. Maturation of a tetravirus capsid alters the dynamic properties and creates a metastable complex. Virology 334:17-27.
94. Zádori Z, Szelei J, Lacoste M-CC, Li Y, Gariépy S, Raymond P, Allaire M, Nabi IR, Tijssen P. 2001. A viral phospholipase A2 is required for parvovirus infectivity. Dev. Cell 1:291-302.
95. Wu Z, Asokan A, Samulski RJ. 2006. Adeno-associated virus serotypes:vector toolkit for human gene therapy. Mol. Ther. 14:316-327.
96. Hauck B, Xiao W. 2003. Characterization of tissue tropism determinants of adeno-associated virus type 1. J. Virol. 77:2768-2774.
97. O'Donnell J, Taylor KA, Chapman MS. 2009. Adeno-associated virus-2 and its primary cellular receptor-cryo-EM structure of a heparin complex. Virology. 385:434-443.
98. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ. 2002. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76:791-801.
99. Bell CL, Vandenberghe LH, Bell P, Limberis MP, Gao GP, Van Vliet K, Agbandje-McKenna M, Wilson JM. 2011. The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J. Clin. Invest. 121:2427-2435.
100. Schmidt M, Govindasamy L, Afione S, Kaludov N, Agbandje-McKenna M, Chiorini JA. 2008. Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adenoassociated virus isolate, AAV(VR-942). J. Virol. 82:8911-8916.
101. Zincarelli C, Soltys S, Rengo G, Koch WJ, Rabinowitz JE. 2010. Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin. Transl. Sci. 3:81-89.
102. Grieger JC, Snowdy S, Samulski RJ. 2006. Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J. Virol. 80:5199-5210.
103. DiMattia MA, Nam HJ, Van Vliet K, Mitchell M, Bennett A, Gurda BL, McKenna R, Olson NH, Sinkovits RS, Potter M, Byrne BJ, Aslanidi G, Zolotukhin S, Muzyczka N, Baker TS, Agbandje-McKenna M. 2012. Structural insight into the unique properties of adenoassociated virus serotype 9. J. Virol. 86:6947-6958.
104. Govindasamy L, Dimattia MA, Gurda BL, Halder S, McKenna R, Chiorini JA, Muzyczka N, Zolotukhin S, Agbandje-McKenna M. 2013. Structural insights into adeno-associated virus serotype 5. J. Virol. 87:11187-11199.
105. Gurda BL, DiMattia MA, Miller EB, Bennett A, McKenna R, Weichert WS, Nelson CD, Chen WJ, Muzyczka N, Olson NH, Sinkovits RS, Chiorini JA, Zolotutkhin S, Kozyreva OG, Samulski RJ, Baker TS, Parrish CR, Agbandje-McKenna M. 2013. Capsid antibodies to different adeno-associated virus serotypes bind common regions. J. Virol. 87:9111-9124.
106. Thomas CE, Storm TA, Huang Z, Kay MA. 2004. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78:3110-3122.